Published in Arthritis Rheum on March 01, 1997
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther (2004) 1.08
Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol (2002) 1.04
Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res (2014) 1.03
The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther (2003) 0.94
Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists. Clin Diagn Lab Immunol (2000) 0.90
Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol (2005) 0.88
Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther (2010) 0.83
Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient! Auto Immun Highlights (2012) 0.83
Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation? J Clin Pathol (2001) 0.82
Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly. Clin Exp Immunol (2004) 0.81
Protein microarrays: a new tool for the study of autoantibodies in immunodeficiency. Front Immunol (2015) 0.80
Mercury, autoimmunity, and environmental factors on cheyenne river sioux tribal lands. Autoimmune Dis (2014) 0.79
Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res Ther (2007) 0.78
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum (1979) 13.72
Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med (1972) 11.51
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol (1982) 9.73
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest (1966) 8.64
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med (1971) 7.46
Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol (1966) 7.40
Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A (1980) 7.33
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromosoma (1985) 6.17
Rheumatoid arthritis. Cell (1996) 6.01
Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid. Science (1968) 5.88
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes (1974) 5.55
Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum (1976) 5.33
A general cardiovascular risk profile: the Framingham Study. Am J Cardiol (1976) 5.10
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med (1975) 5.00
Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med (1979) 4.94
Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol (1971) 4.90
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J (1989) 4.69
Major determinants of the specificity of interaction between small nuclear ribonucleoproteins U1A and U2B'' and their cognate RNAs. Nature (1990) 4.67
Antibodies to cellular antigens in Sjögren's syndrome. J Clin Invest (1975) 4.62
HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation (1977) 4.47
Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus. J Immunol (1969) 4.45
Polymyositis: an overdiagnosed entity. Neurology (2003) 4.36
Autoantibody to a nuclear antigen in proliferating cells. J Immunol (1978) 4.36
Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med (1970) 4.11
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum (1976) 4.02
Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin. J Exp Med (1991) 4.02
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum (1980) 3.87
Cytokinesis and midzone microtubule organization in Caenorhabditis elegans require the kinesin-like protein ZEN-4. Mol Biol Cell (1998) 3.69
Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol (1998) 3.68
Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine. J Biol Chem (1985) 3.60
Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol (1971) 3.59
The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med (1980) 3.59
Presence of anti-Sm reactivity in autoimmune mouse strains. J Exp Med (1978) 3.58
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med (1976) 3.50
cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins. EMBO J (1987) 3.47
A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45
Immunological and ultrastructural studies of the nuclear coiled body with autoimmune antibodies. Exp Cell Res (1991) 3.44
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer (2001) 3.23
The recent decrease in CHD mortality. Prev Med (1975) 3.16
Premature mortality from coronary heart disease. The Framingham study. JAMA (1971) 3.15
Monoclonal autoantibody from a (New Zealand black x New Zealand white)F1 mouse and some human scleroderma sera target an Mr 34,000 nucleolar protein of the U3 RNP particle. Arthritis Rheum (1987) 3.09
Physical association of two nuclear antigens and mutual occurrence of their antibodies: the relationship of the SM and RNAprotein (MO) systems in SLE sera. J Immunol (1973) 3.07
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen. Arthritis Rheum (1974) 2.99
Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem (1979) 2.99
A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med (1988) 2.98
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med (1969) 2.88
hnRNA and its attachment to a nuclear protein matrix. J Cell Biol (1981) 2.88
A nuclear antigen associated with cell proliferation and blast transformation. J Exp Med (1981) 2.82
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Death and coronary attacks in men after giving up cigarette smoking. A report from the Framingham study. Lancet (1974) 2.81
Labile hypertension: a faulty concept? The Framingham study. Circulation (1980) 2.76
Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. Proc Natl Acad Sci U S A (1987) 2.75
Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation (1975) 2.74
Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res (1986) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Use of glutaraldehyde as a coupling agent for proteins and peptides. Methods Enzymol (1980) 2.73
Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus. J Lab Clin Med (1967) 2.71
Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr (1996) 2.70
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69